| Literature DB >> 26414336 |
Alessandra Mazzola1,2, Andrea Costantino1, Salvatore Petta1, Tommaso Vincenzo Bartolotta3, Maurizio Raineri4, Rodolfo Sacco5, Giuseppe Brancatelli3, Calogero Cammà1, Giuseppe Cabibbo1.
Abstract
Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70-85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. The aim of this review is to underline the main concerns, pitfalls and warnings for these patients.Entities:
Keywords: hepatocellular carcinoma; immunosuppression; liver transplantation; living donors; recurrence
Mesh：
Substances：
Year: 2015 PMID： 26414336 DOI： 10.2217/fon.15.239
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404